Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Total Enrollment
10 participants
Study Classification
OBSERVATIONAL
Study Start Date
2017-01-01
Study Completion Date
2019-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Severe burn patients are some of the most challenging critically ill patients with an extreme and continuous state of physiological stress. Patients tends to stay for a long period of time in intensive care unit to treat burns as well as dealing with complications that arises from the initial burns injury. Severe burns patients are notoriously known to loose weight. The word 'catabolism' is used medically. This theory of catabolism after a trauma was hypothesised in 1942 by Professor Curthberston and based on animal models. Since this date, despite medical technological advancement, there has been no research that confirms Professor Curthberston's theory. Investigators still do not know the exact mechanism by which the body changes from conserving energy to becoming catabolic. Furthermore, it remains unclear whether this change in catabolism is necessary to heal from burns injury.
This theoretical catabolism in burns patients is currently treated with nutritional supplement, use of medications including beta-blockers (suppresses heart rate and decreases blood pressure) and oxandrolone (formula which is similar to testosterone to build up muscles).
There are evidences to suggest that increase in weight loss worsens the outcome in burns injury. Both overfeeding or underfeeding patients can be detrimental. In this research, the exact changes in metabolic rate will be measured in the first 72 hours of the study using a calorimetry machine. In addition to the metabolic rate, the response to the heart, liver, kidneys and hormonal levels will be measured. By looking into these dynamic changes the investigator will be able to elucidate whether there is a real increase in metabolic rate. If there is, the investigator would also be able to tell the response of different organs and whether there are any hormones that could be responsible to inflicting the metabolic changes.
This theoretical catabolism in burns patients is currently treated with nutritional supplement, use of medications including beta-blockers (suppresses heart rate and decreases blood pressure) and oxandrolone (formula which is similar to testosterone to build up muscles).
There are evidences to suggest that increase in weight loss worsens the outcome in burns injury. Both overfeeding or underfeeding patients can be detrimental. In this research, the exact changes in metabolic rate will be measured in the first 72 hours of the study using a calorimetry machine. In addition to the metabolic rate, the response to the heart, liver, kidneys and hormonal levels will be measured. By looking into these dynamic changes the investigator will be able to elucidate whether there is a real increase in metabolic rate. If there is, the investigator would also be able to tell the response of different organs and whether there are any hormones that could be responsible to inflicting the metabolic changes.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Longitudinal Investigation of Energy Expenditure and Substrate Utilization in Critically Ill Patients
NCT05124860
Critical Illness
COMPLETED
Metabolic and Nutritional Characteristics of Long-stayer ICU Patients
NCT03938961
Critically Ill
COMPLETED
Energy Expenditure in ICU Patients Using Predictive Formulas and Various Body Weights Versus Indirect Calorimetry
NCT02552446
Critical Illness
Body Weights
COMPLETED
Hematocrit Evolution in Severe Burns
NCT05569499
Severe Skin Burns
COMPLETED
Predictive Factors, Demographics and Mortality for ARDS in Burn Patients
NCT03807232
ARDS, Human
Burns
Lung Diseases
COMPLETED
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. Purpose of the study The purpose of this study is to gain a better understanding of the acute physiological and metabolic changes in severe burns injury. Unless clinicians understand the physiological effect in burns patients, clinicians are unable to develop new therapeutic interventions to halt the hyper metabolic changes in burns patient. This research will be looking into the acute resting basal metabolic changes in severe adult burns patients by using Quark RMR (indirect calorimetry). This equipment will allow the investigator to detect the metabolic switch in severe burns patients.
In addition to the metabolic changes, 'Estimated cardiac output monitor' will be placed in conjunction with calculating the Fick principle. Heart rate and pulse oximeter will be monitored continuously. These adjuncts will allow the investigator to conclude whether hyper-metabolism is associated with hyper dynamic cardiovascular response to burns.
Splanchnic circulation will be monitored using the LiMON indocyanine green test and intermittent intra-abdominal pressure will be monitored to assess whether there is a link between the metabolic rate and splanchnic circulation.
2. Objectives
1. Primary Objective:
Identifying the 'Ebb' phase and 'Flow' phase in acute burns injury
2. Secondary Objectives:
1\. To establish cardiovascular response to burns in the acute phase.
a. To establish cardiovascular response to hyper-catabolism, using ESCO (estimated cardiac output) 2. To asses the relationship between the splanchnic circulation and hyper-catabolism 3. To assess the feasibility of performing LiMON test and (Bispectral Index) BIS monitoring for future (Burns Intensive Care Unit) BICU patients 4. To optimize dietary recommendations for patients who are suffering from hyper-catabolic state
8\. Study Design Summary: This is a prospective, observational study with intensive monitoring but no experimental intervention
a) Study Site and Duration: This study will be conducted on the adult Burns Intensive Care Unit (BICU), Chelsea and Westminster Foundation Trust, London, United Kingdom (UK). This is a tertiary referral hospital serving an area of North West London. The average annual admission for severe burns to BICU varies form 10 -15 patients. The study will be conducted from December 2015 to December 2019.
The BICU has facilities for ventilatory support, sedation and surgery of critically ill patients, with two-bed intensive care unit. Each bed is isolated with three senior trained intensive care nurses covering 24 hours. Critically ill burns participants will be monitored continuously by nurses and doctors with the use of non-invasive and invasive monitoring depending on their clinical needs as per standard clinical care.
f) Procedure
General History and Examination Upon enrolment, full history and examination will be performed, including detailed assessment of the respiratory system, extent and depth of burns, neurological examination, cardiovascular examination and excluding other potential trauma that the participants could have suffered from.
The results will be recorded on a designated record form. Participants will be re-assessed by a physician or nurse for the duration of continuous monitoring to independently assess blood pressure, heart rate, respiratory rate, oxygen saturation, cardiac output, Glasgow coma scale, sedation score, ventilator requirement, urine output, intra-abdominal pressure, splanchnic circulation, BIS, EEG, nitrogen balance, resting metabolic rate and temperature.
Daily follow up will include assessment for any complications of burns including sepsis, infection, inhalational injury, suspected Acute Respiratory Distress Syndrome, and suspected respiratory distress of uncertain aetiology. The decision to obtain imaging or other investigations to assess such complications will be made by the clinical team and the results will be archived as source documents.
In addition to above, venous blood sample will be taken to establish on the daily basis to monitor inflammatory markers, renal, liver, bone marrow function, electrolyte levels. Urinary nitrogen levels, plasma hormones including Thyroid stimulating hormone, T3, T4, cortisol levels, insulin, glucagon levels are taken daily. These tests will be completed by the clinical team.
Regular arterial line gas sample will be taken as guided by the clinical team.
Continuous monitoring Participants will undergo standard electrophysiological monitoring, cardiovascular monitoring including arterial line blood pressure monitoring, placement of estimated cardiac output monitoring and intra-abdominal pressure. These devices will be connected to a portable diagnostic recording system to aid the diagnosis of any physiological changes that occurs. The system comprises a central device, with a display screen, battery pack and memory card. The electrophysiological monitoring device will consists or three electrodes and wires which feeds into the central device ports. The electrodes will be attached to the participants' forehead; left central and right. The intra-abdominal pressure device consists of a transducer which is located in the urinary catheter. The wires which are connected to the transducers are then fed into the central device ports. The continuous estimated cardiac output monitoring devices consist of three cardiac electrodes, pulse oximetry device and wires, which are connected to the central device ports. The cardiac electrodes are placed to the participants' thorax and the pulse oximetry device is attached to the participants' digit either in the foot or hand.
The following sensors will be applied:
* Electrocardiogram: recording cardiac electrical activity to give three recorded and three derived traces
* Ventilator: recording airflow inhale and exhalation, flow rate, pressure, tidal volume, peep, type of ventilator mode.
* Pulse oximeter: recording arterial oxygen saturation and pulse rate The monitoring system will be applied to the participant once assent is obtained and after the initial management; drug administration, examination and other investigation are performed by the clinical team. The sensors will be applied with the goal of recording continuously for seventy two hours.
Intermittent monitoring Participant will undergo indirect calorimetry monitoring and LIMON test. Resting metabolic rate will be measured every 12 hourly for 72 hours using indirect calorimetry with Quark Resting Metabolic Rate (QUARK RMR) (COSMED, Rome, Italy). This device consist of canopy, ventilator tubing, heat and moisture exchange filter, air sample analyzing tubes, computer, gas analyzing chamber, calibration gas cylinder, air pump to calibrate the flow sensor, fuel cell, spirometry and Windows 8.0 computer which has COSMED Quark RMR software installed.
Participants are either ventilated or awake. Ventilated participants will have a gas analyzing tubing attached to the heat and moisture exchange filter which is fed unto the gas analyzing chamber. The flow meter is attached at the exhaust port at the back of the ventilator.
The measurement is taken until a steady resting state is achieved. This will normally vary from two minutes to 20 minutes. The results are automatically recorded onto the Quark RMR software. In order to achieve steady ventilation with little minimum bias flow the participants' Bispectral index is maintained between forty and sixty using medications such as propofol, fentanyl, midazolam or clonidine.
Liver and splanchnic circulation will be measured every 6 hourly using LIMON Liver Function Monitor (Liver Monitor, PULSION Medical Systems, Munich, Germany) The device consist of sensor, wires and monitor to display the instructions and results. The sensor is attached to the participants' earlobe, finger tips in the hand or foot. The indocyanine green dye (ICG) is injected into a vein. The results will be displayed onto the monitor.
If the recording is suboptimal due to loss of sensors or insufficient recording, it will be repeated.
All of the above equipments and monitoring system will be cleaned and disinfected according to the manufacturing advice and microbiology team. The standard operating procedures for the above equipments are described in the appendix.
Cessation of monitoring The recording system, or individual sensors will be removed immediately if it is required for clinical investigations or interventions. However, it is anticipated that most investigations and interventions will be able to proceed with the sensors in place. The device is expected to remain in place during patient re-positioning, airway management, delivery of oxygen, delivery of oral and IV medication and fluids and most imaging with the exception of magnetic resonance imaging.
BIS monitoring will be removed in the event of cardio-respiratory arrest. If study clinician is not present at the time of cardio-respiratory arrest, the monitor will detach without difficulty and will not impede or delay resuscitation efforts.
Date collection:
In addition to above data, the investigator be collecting the patients' demographics including apache II scoring, end organ function including liver function, renal function, haematological status, ventilator settings, arterial gas, urine output and temperature.
9\. Data Analysis Analysis of recording Data will be exported from the monitoring devices after each recording and assessed for adequacy and quality.
All frontal lobe electroencephalogram will be analysed. If there is any EEG finding that are consist with seizures it will be reviewed by neurophysiologist. All resting metabolic rate will be plotted against the physiological parameters including splanchnic circulation, temperature and intra-abdominal pressure. The ECG will be reviewed to assess heart rate, rhythm and conduction. Invasive blood pressure monitoring device will assess the blood pressure. Estimated cardiac output monitoring will assess the cardiac output and the trend over the seventy two hours. Fick principle will be used to calculate the cardiac output using the data (CaO2 and CVO2) obtained from the Quark RMR.
Any stimulus, airway management, changes in the levels of sedation, return from theatres will be noted.
1. Statistical Consideration In the view of the complexity of data provided by continuous monitoring, statistical guidance will be sought at all stages of analysis from the "Statistician. For the primary end points, the investigator will draw a graph of time again resting metabolic rate. The precise choice of test will be determined once the distribution pattern of the data is known. Repeated measure analysis of variance will be used followed by regression analysis accounted for repeat measures.
In comparing patient specific outcome measures (mortality, requirement for ventilation, development of complications such as sepsis), participants will be placed into ranked groups from most to least difference in trend change in resting metabolic rate and nonparametric analysis will be used to assess the relationship between mortality or morbidity and resting metabolic rate.
2. Sample Size Justification Primary determinant is expected number of eligible patients presenting in the duration of study.
Power calculation was completed for the primary outcome measures. In order to conclude to show that there is an increase in metabolic rate by 200 kcal per day with a power of 0.8, I will need 8 patients to be able to conclude that there increase in metabolic rate.
In addition to the metabolic changes, 'Estimated cardiac output monitor' will be placed in conjunction with calculating the Fick principle. Heart rate and pulse oximeter will be monitored continuously. These adjuncts will allow the investigator to conclude whether hyper-metabolism is associated with hyper dynamic cardiovascular response to burns.
Splanchnic circulation will be monitored using the LiMON indocyanine green test and intermittent intra-abdominal pressure will be monitored to assess whether there is a link between the metabolic rate and splanchnic circulation.
2. Objectives
1. Primary Objective:
Identifying the 'Ebb' phase and 'Flow' phase in acute burns injury
2. Secondary Objectives:
1\. To establish cardiovascular response to burns in the acute phase.
a. To establish cardiovascular response to hyper-catabolism, using ESCO (estimated cardiac output) 2. To asses the relationship between the splanchnic circulation and hyper-catabolism 3. To assess the feasibility of performing LiMON test and (Bispectral Index) BIS monitoring for future (Burns Intensive Care Unit) BICU patients 4. To optimize dietary recommendations for patients who are suffering from hyper-catabolic state
8\. Study Design Summary: This is a prospective, observational study with intensive monitoring but no experimental intervention
a) Study Site and Duration: This study will be conducted on the adult Burns Intensive Care Unit (BICU), Chelsea and Westminster Foundation Trust, London, United Kingdom (UK). This is a tertiary referral hospital serving an area of North West London. The average annual admission for severe burns to BICU varies form 10 -15 patients. The study will be conducted from December 2015 to December 2019.
The BICU has facilities for ventilatory support, sedation and surgery of critically ill patients, with two-bed intensive care unit. Each bed is isolated with three senior trained intensive care nurses covering 24 hours. Critically ill burns participants will be monitored continuously by nurses and doctors with the use of non-invasive and invasive monitoring depending on their clinical needs as per standard clinical care.
f) Procedure
General History and Examination Upon enrolment, full history and examination will be performed, including detailed assessment of the respiratory system, extent and depth of burns, neurological examination, cardiovascular examination and excluding other potential trauma that the participants could have suffered from.
The results will be recorded on a designated record form. Participants will be re-assessed by a physician or nurse for the duration of continuous monitoring to independently assess blood pressure, heart rate, respiratory rate, oxygen saturation, cardiac output, Glasgow coma scale, sedation score, ventilator requirement, urine output, intra-abdominal pressure, splanchnic circulation, BIS, EEG, nitrogen balance, resting metabolic rate and temperature.
Daily follow up will include assessment for any complications of burns including sepsis, infection, inhalational injury, suspected Acute Respiratory Distress Syndrome, and suspected respiratory distress of uncertain aetiology. The decision to obtain imaging or other investigations to assess such complications will be made by the clinical team and the results will be archived as source documents.
In addition to above, venous blood sample will be taken to establish on the daily basis to monitor inflammatory markers, renal, liver, bone marrow function, electrolyte levels. Urinary nitrogen levels, plasma hormones including Thyroid stimulating hormone, T3, T4, cortisol levels, insulin, glucagon levels are taken daily. These tests will be completed by the clinical team.
Regular arterial line gas sample will be taken as guided by the clinical team.
Continuous monitoring Participants will undergo standard electrophysiological monitoring, cardiovascular monitoring including arterial line blood pressure monitoring, placement of estimated cardiac output monitoring and intra-abdominal pressure. These devices will be connected to a portable diagnostic recording system to aid the diagnosis of any physiological changes that occurs. The system comprises a central device, with a display screen, battery pack and memory card. The electrophysiological monitoring device will consists or three electrodes and wires which feeds into the central device ports. The electrodes will be attached to the participants' forehead; left central and right. The intra-abdominal pressure device consists of a transducer which is located in the urinary catheter. The wires which are connected to the transducers are then fed into the central device ports. The continuous estimated cardiac output monitoring devices consist of three cardiac electrodes, pulse oximetry device and wires, which are connected to the central device ports. The cardiac electrodes are placed to the participants' thorax and the pulse oximetry device is attached to the participants' digit either in the foot or hand.
The following sensors will be applied:
* Electrocardiogram: recording cardiac electrical activity to give three recorded and three derived traces
* Ventilator: recording airflow inhale and exhalation, flow rate, pressure, tidal volume, peep, type of ventilator mode.
* Pulse oximeter: recording arterial oxygen saturation and pulse rate The monitoring system will be applied to the participant once assent is obtained and after the initial management; drug administration, examination and other investigation are performed by the clinical team. The sensors will be applied with the goal of recording continuously for seventy two hours.
Intermittent monitoring Participant will undergo indirect calorimetry monitoring and LIMON test. Resting metabolic rate will be measured every 12 hourly for 72 hours using indirect calorimetry with Quark Resting Metabolic Rate (QUARK RMR) (COSMED, Rome, Italy). This device consist of canopy, ventilator tubing, heat and moisture exchange filter, air sample analyzing tubes, computer, gas analyzing chamber, calibration gas cylinder, air pump to calibrate the flow sensor, fuel cell, spirometry and Windows 8.0 computer which has COSMED Quark RMR software installed.
Participants are either ventilated or awake. Ventilated participants will have a gas analyzing tubing attached to the heat and moisture exchange filter which is fed unto the gas analyzing chamber. The flow meter is attached at the exhaust port at the back of the ventilator.
The measurement is taken until a steady resting state is achieved. This will normally vary from two minutes to 20 minutes. The results are automatically recorded onto the Quark RMR software. In order to achieve steady ventilation with little minimum bias flow the participants' Bispectral index is maintained between forty and sixty using medications such as propofol, fentanyl, midazolam or clonidine.
Liver and splanchnic circulation will be measured every 6 hourly using LIMON Liver Function Monitor (Liver Monitor, PULSION Medical Systems, Munich, Germany) The device consist of sensor, wires and monitor to display the instructions and results. The sensor is attached to the participants' earlobe, finger tips in the hand or foot. The indocyanine green dye (ICG) is injected into a vein. The results will be displayed onto the monitor.
If the recording is suboptimal due to loss of sensors or insufficient recording, it will be repeated.
All of the above equipments and monitoring system will be cleaned and disinfected according to the manufacturing advice and microbiology team. The standard operating procedures for the above equipments are described in the appendix.
Cessation of monitoring The recording system, or individual sensors will be removed immediately if it is required for clinical investigations or interventions. However, it is anticipated that most investigations and interventions will be able to proceed with the sensors in place. The device is expected to remain in place during patient re-positioning, airway management, delivery of oxygen, delivery of oral and IV medication and fluids and most imaging with the exception of magnetic resonance imaging.
BIS monitoring will be removed in the event of cardio-respiratory arrest. If study clinician is not present at the time of cardio-respiratory arrest, the monitor will detach without difficulty and will not impede or delay resuscitation efforts.
Date collection:
In addition to above data, the investigator be collecting the patients' demographics including apache II scoring, end organ function including liver function, renal function, haematological status, ventilator settings, arterial gas, urine output and temperature.
9\. Data Analysis Analysis of recording Data will be exported from the monitoring devices after each recording and assessed for adequacy and quality.
All frontal lobe electroencephalogram will be analysed. If there is any EEG finding that are consist with seizures it will be reviewed by neurophysiologist. All resting metabolic rate will be plotted against the physiological parameters including splanchnic circulation, temperature and intra-abdominal pressure. The ECG will be reviewed to assess heart rate, rhythm and conduction. Invasive blood pressure monitoring device will assess the blood pressure. Estimated cardiac output monitoring will assess the cardiac output and the trend over the seventy two hours. Fick principle will be used to calculate the cardiac output using the data (CaO2 and CVO2) obtained from the Quark RMR.
Any stimulus, airway management, changes in the levels of sedation, return from theatres will be noted.
1. Statistical Consideration In the view of the complexity of data provided by continuous monitoring, statistical guidance will be sought at all stages of analysis from the "Statistician. For the primary end points, the investigator will draw a graph of time again resting metabolic rate. The precise choice of test will be determined once the distribution pattern of the data is known. Repeated measure analysis of variance will be used followed by regression analysis accounted for repeat measures.
In comparing patient specific outcome measures (mortality, requirement for ventilation, development of complications such as sepsis), participants will be placed into ranked groups from most to least difference in trend change in resting metabolic rate and nonparametric analysis will be used to assess the relationship between mortality or morbidity and resting metabolic rate.
2. Sample Size Justification Primary determinant is expected number of eligible patients presenting in the duration of study.
Power calculation was completed for the primary outcome measures. In order to conclude to show that there is an increase in metabolic rate by 200 kcal per day with a power of 0.8, I will need 8 patients to be able to conclude that there increase in metabolic rate.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Burns
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
COHORT
Study Time Perspective
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
observational study
No intervention
Intervention Type
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male or female, aged 16 years or over
* Informed, written consent from patient. If the participant is unable to give consent then assent will be considered.
* Burns more than 15%
* Acute presentation
* Informed, written consent from patient. If the participant is unable to give consent then assent will be considered.
* Burns more than 15%
* Acute presentation
Exclusion Criteria
* Any concern from the clinical team that the application or ongoing presence of the monitoring device would interfere with optimal patient management.
* Allergy to adhesives used for monitor leads and belts.
* Participants below 16 years old
* Burns less than 5%
* Conditions that gives an inaccurate calorimetry results
* Participants needing oxygen concentration more than 60%
* Participants who have broncho-alveolar fistula
* Participants with chest drains
* Airway leak within the ventilated systems
* Allergy to adhesives used for monitor leads and belts.
* Participants below 16 years old
* Burns less than 5%
* Conditions that gives an inaccurate calorimetry results
* Participants needing oxygen concentration more than 60%
* Participants who have broncho-alveolar fistula
* Participants with chest drains
* Airway leak within the ventilated systems
Minimum Eligible Age
16 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chelsea and Westminster NHS Foundation Trust
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Marcela P. Vizcaychipi
Consultant in Anaesthesia and Intensive Care Medicine Honorary Senior Clinical Lecturer Divisional Research Lead for Planned Care Surgery and Clinical Support
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Marcela Vizcaychipi
Role: PRINCIPAL_INVESTIGATOR
Chelsea and Westminster NHS trust
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Burn Intensive Care Unit (BICU), Chelsea and Westminster Hospital
London, , United Kingdom
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
United Kingdom
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Herndon DN, Hart DW, Wolf SE, Chinkes DL, Wolfe RR. Reversal of catabolism by beta-blockade after severe burns. N Engl J Med. 2001 Oct 25;345(17):1223-9. doi: 10.1056/NEJMoa010342.
Reference Type
RESULT
Huang YS, Yang ZC, Liu XS, Chen FM, He BB, Li A, Crowther RS. Serial experimental and clinical studies on the pathogenesis of multiple organ dysfunction syndrome (MODS) in severe burns. Burns. 1998 Dec;24(8):706-16. doi: 10.1016/s0305-4179(98)00123-5.
Reference Type
RESULT
Jeschke MG, Gauglitz GG, Kulp GA, Finnerty CC, Williams FN, Kraft R, Suman OE, Mlcak RP, Herndon DN. Long-term persistance of the pathophysiologic response to severe burn injury. PLoS One. 2011;6(7):e21245. doi: 10.1371/journal.pone.0021245. Epub 2011 Jul 18.
Reference Type
RESULT
Jeschke MG, Herndon DN, Wolf SE, DebRoy MA, Rai J, Lichtenbelt BJ, Barrow RE. Recombinant human growth hormone alters acute phase reactant proteins, cytokine expression, and liver morphology in burned rats. J Surg Res. 1999 May 15;83(2):122-9. doi: 10.1006/jsre.1999.5577.
Reference Type
RESULT
Kasten KR, Makley AT, Kagan RJ. Update on the critical care management of severe burns. J Intensive Care Med. 2011 Jul-Aug;26(4):223-36. doi: 10.1177/0885066610390869.
Reference Type
RESULT
CUTHBERTSON DP. Interrelationship of metabolic changes consequent to injury. Br Med Bull. 1954;10(1):33-7. doi: 10.1093/oxfordjournals.bmb.a069369. No abstract available.
Reference Type
RESULT
CUTHBERTSON DP. Nutrition. Annu Rev Med. 1953;4:135-62. doi: 10.1146/annurev.me.04.020153.001031. No abstract available.
Reference Type
RESULT
Bell JR, Clark AM, Cuthbertson DP. Experimental traumatic shock. J Physiol. 1938 May 14;92(4):361-70. doi: 10.1113/jphysiol.1938.sp003608. No abstract available.
Reference Type
RESULT
Cathcart EP, Cuthbertson DP. The composition and distribution of the fatty substances of the human subject. J Physiol. 1931 Jul 6;72(3):349-60. doi: 10.1113/jphysiol.1931.sp002779. No abstract available.
Reference Type
RESULT
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
qw
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Prevalence Rate, and Clinical Characteristics of Obesity Hypoventilation Syndrome Via Screening Patients Admitted to Medical Intensive Care Units
NCT02934581
COMPLETED
Prevalence of Pressure Ulcers Among Critically Ill Patients and Factors Associated With Their Occurrence in the ICU
NCT03912467
COMPLETED
Disease Severity, Mortality Risk, and Muscle Function in Intensive Care Unit Patients
NCT07124442
RECRUITING
Prevalence and Outcome of Hypermetabolism in Initial Prevalence and Outcome of Hypermetabolism in Initial Phase of Intensive Care Unit Patient: a Prospective Observational Study
NCT02002676
UNKNOWN
Burden, Mortality and Supply Costs in Intensive Care Unit Patients
NCT04094428
RECRUITING
Mitochondrial Assessment in Critical Ill Patients in Intensive Care
NCT07018843
NOT_YET_RECRUITING
Musculoskeletal Ultrasound Study in Critical Care: Longitudinal Evaluation
NCT01106300
COMPLETED
Ovarian Reserve in Intensive Care Patients
NCT06999291
NOT_YET_RECRUITING
Effects of Patient-centered Skin Care in Critical Care
NCT05948306
COMPLETED
NA
Indirect Calorimetry Versus Urea-creatinine Ratio to Evaluate Catabolism in Critically Ill Patients
NCT06244381
COMPLETED
Sepsis Pathophysiological & Organisational Timing
NCT01099813
COMPLETED
Sepsis Metabolomics
NCT01649440
COMPLETED
Monitoring the Clinical and Immunological Effects of Microbiome Changes Following Severe Burn Injury
NCT07329595
RECRUITING
Braden Pressure Ulcer Scale for Prediction of the Intensive Care Length of Stay
NCT06697340
COMPLETED
Clinical Empirical Research of ARDS
NCT05922826
RECRUITING
Burnout Syndrome Among Medical Residents
NCT03668080
COMPLETED
Scoring System for Inhalation Injury
NCT01194024
COMPLETED
Protocol of Management of Major Pediatric Burn in Intensive Care Unit
NCT04192942
UNKNOWN
NA
Analysis of Risk Factors and Prognostic Predictive Value in Sepsis Patients With Nutritional Risk
NCT07278167
COMPLETED
Impact of Extra Corporal Membrane Oxygenation Services on Burnout Development in Intensive Care Units.
NCT04620005
COMPLETED
ICIS in Burn Patients Compared to Other Inflammatory Markers
NCT04894500
COMPLETED
Nutrition Practice in Critically Ill Adults
NCT06576895
RECRUITING
An Investigation of the Effect of Types of Catheters on Bloodstream Infection in Patients With Major Burns: Prediction With Procalcitonin and Prognosis
NCT05581316
COMPLETED
NA